Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
14 déc. 2023 19h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics...
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
22 sept. 2023 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics...
Neurogene and Neoleukin Announce Definitive Merger Agreement
18 juil. 2023 06h30 HE
|
Neoleukin Therapeutics, Inc.
Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene’s differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected...
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
08 mars 2023 17h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
12 déc. 2022 13h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
14 nov. 2022 16h03 HE
|
Neoleukin Therapeutics, Inc.
-- Development of NL-201 to be discontinued for strategic reasons ---- Company to focus on next-generation de novo proteins and core technology ---- Company restructuring to extend cash runway into...
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
03 nov. 2022 09h05 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
09 août 2022 16h02 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo...
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
03 août 2022 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de...
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
27 juil. 2022 08h00 HE
|
Neoleukin Therapeutics, Inc.
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022...